Nuclear receptor binding agents
US8637706B2 · kind B2 · utility
5Cited by
22References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 31, 2012 |
| Grant date | Jan 28, 2014 |
| Priority date | — |
| Expiry date | Jul 6, 2032 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.